Oral mucositis (OM) is a painful and debilitating complication of cancer therapy that can adversely affect patients' treatment regimens and quality of life.

While the mechanism of action of SalivaMAX™ is unknown it is hypothesized that the high concentration of calcium ions diffuses into the intracellular spaces in the epithelium and bathe the mucosal lesions.¹ It is well known that calcium ions play an essential function in the inflammatory process, namely tissue repair and the blood clotting cascade. Phosphate ions also provide a comparable role in maintaining proper cellular health and healing damaged mucosa.

Go With What Works!

✓ SalivaMAX™ is proven to help restore oral health:

- Relieves symptoms
- Reduces discomfort caused by dryness
- Helps to mend painful tissue

Oral Mucositis Prevalence



20-40%

of patients undergoing conventional chemo



80%

of patients undergoing high dose chemo



+95%

of patients undergoing H&N radiation therapy



SalivaMAX[™] is easy to use:

- Mix SalivaMAX[™] packet with 1 oz. of water; creates a supersaturated calcium phosphate rinse
- Swish with 1/2 of solution for 1 minute and spit out. Repeat with second half
- Repeat up to 10 times per day depending on severity


SalivaMAX™ is gentle:

- Nonsystemic swish & spit
- Has no anticipated side effects
- No known interactions with other medications

SalivaMAX™ Indications



- Aids in maintaining the proper ionic balance needed for a healthy oral cavity
- Provides intensive hygiene of the oral cavity
- Relieves dryness of the oral mucosa which is associated with an amelioration of pain
- An adjunct to reducing the oral side effects of chemotherapy and radiation





"Not only has SalivaMAX" reduced the severity of mucositis, it has pushed back the onset by almost one month."

- JB (Oncology Clinician)



• at a Regional Cancer Center, the above percentage of patients found an **improvement** in their respective symptoms.

Clinical Research:



Quinn provided a review of thirty studies and found that the majority (24) reported that a supersaturated calcium phosphate rinse was efficacious at reducing the mucositis grade and/or duration as well as the mucositic pain associated with the condition.²

This is the first published study to determine the efficacy of a supersaturated calcium phosphate oral rinse on patients with solid tumors (breast cancer) in response to chemotherapy-induced mucositis. Although this was a single sided study, the short time to elimination of mucositis was noteworthy: resolution of Grade 3 mucositis was an average of 4 days and Grade 2, 3.5 days.³

Taylor evaluated the cost benefit of using a supersaturated calcium phosphate rinse for treating oral mucositis in patients undergoing conditioning therapy for bone marrow transplantation (high dose chemo) and head and neck cancer (chemo and radiation therapy). The net savings of using a supersaturated calcium phosphate rinse over the standard of care was \$5,582 and ranging \$475 - \$6,695, for each patient in addition to the positive clinical outcomes.⁴

Markiewicz evaluated supersaturated calcium phosphate rinse compared to the standard of care, topical mouth solutions, in patients undergoing high dose chemotherapy. The supersaturated calcium phosphate group showed statistically significant improvements over the control group.⁵

2. Quinn et al. Efficacy of a supersaturated calcium phosphate oral rinse for the prevention and treatment of oral mucositis in patients receiving high-dose cancer therapy: a review of current data. Eur J Cancer Care. 22:564-579;2013. 3. Younus et al. Treatment of Active Mucositis With Caphosol (Calcium Phosphate): A Retrospective Case-Series. World J Oncol. 4(3):147-150;2013. 4. Taylor. A Business Impact Study of the Use of a Supersaturated Calcium Phosphate Oral Rinse (SCPOR) in the Prevention and Treatment of Oral Mucositis. Clin Med Diags. 3(4):82-87;2013. 5. Markiewicz et al. Treating oral mucositis with a supersaturated calcium phosphate rinse: comparison with control in patients undergoing allogeneic hematopoietic stem cell transplantation. Support Care Cancer. 20:2223-2229;2012.

FS-4797v1.0